Butyrate gives gut lining lasting anti-inflammation
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Northwestern Medicine researchers published a Nature Communications study showing butyrate, a short-chain fatty acid produced when gut bacteria ferment dietary fiber, reprograms intestinal epithelial cells (IECs) so they continue promoting anti-inflammatory immune responses after the compound is gone.
- In mice given butyrate in drinking water, CD4+ T-cells still produced elevated IL-10 two weeks after treatment ended, and the mice lost less weight, showed lower inflammatory markers, and developed less severe tissue damage after chemically induced colitis.
- The protective effect did not depend on changes to the gut microbiome—even germ-free mice given butyrate showed a sustained immunoregulatory environment, according to the study.
- Researchers traced the mechanism to sustained transcriptional and epigenetic activation of Sat1 in IECs, which produces the metabolite N1-acetylspermidine—a compound that contributed to IL-10 production in T-cells.
- Conditioned medium from butyrate-treated mouse and human IECs strongly induced IL-10-producing CD4+ T-cells in culture, the team reported.
- The study was led by Yingzi Cong, PhD (senior and co-corresponding author) and Tianming Yu, PhD (first and co-corresponding author), with co-authors Wenjing Yang, Suxia Yao, and Parambir Dulai, and was funded by NIH grants DK135193, DK124132, and DK145439.
Why it matters: For inflammatory bowel disease research, the study identifies a concrete molecular target—the butyrate-Sat1-N1-acetylspermidine pathway—worth testing directly in human intestinal tissue. It also reframes gut epithelial cells from passive barriers into cells that store molecular memory, opening a new line of investigation into how diet-derived metabolites sustain immune tolerance in IBD patients.
Ask SkimNews
